A Phase 1 interventional study of brentuximab vedotin and Placebo in Human Immunodeficiency Virus, sponsored by Seagen Inc.. Withdrawn at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-14.
Sponsored by Seagen Inc. (part of Pfizer) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will test brentuximab vedotin to see if it is safe for people with human immunodeficiency virus (HIV) who have low CD4+ and have received antiretroviral therapy (ART) treatment. It will also see if brentuximab vedotin raises CD4+ counts. It will study the side effects of this drug as well. A side effect is anything a drug does to the body besides treating the disease.
In this study participants will be assigned randomly to a group. Participants will get either brentuximab vedotin or placebo. A placebo looks like the drug but does not contain any medicine in it. All participants will keep getting ART during the study.
3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.
Browse Acquired Immunodeficiency Syndrome studies →Seagen Inc. is the lead sponsor of 88 studies on the registry; 1 is open to participants now.
Of its 27 completed or terminated interventional studies of FDA-regulated products, 14 (52%) have results posted.
First submitted before Seagen Inc. became part of Pfizer.
Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Immunological nonresponder, defined as:
Exclusion Criteria:
Any currently active AIDS-defining illness per Category C conditions according to the CDC Classification System for Infection, with the following exceptions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brentuximab vedotin given on Day 1 and Day 15. ART will be given throughout the study.
Drug: brentuximab vedotin · Drug: ART
Placebo given on Day 1 and Day 15. ART will be given throughout the study.
Drug: Placebo · Drug: ART
Given into the vein (IV; intravenously)
Also known as: ADCETRIS
Given by IV
Daily use of a combination of HIV medicines
Number of participants with adverse events (AEs)
Any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment
Time frame: Through 30 days after last study treatment
Number of participants with laboratory abnormalities
Time frame: Approximately 1 year
Number of participants with dose-limiting toxicities (DLTs) by dose level
Time frame: Up to 30 days
Area under the concentration-time curve (AUC)
Pharmacokinetic (PK) Parameter
Time frame: Approximately 4 months
Maximum concentration (Cmax)
PK Parameter
Time frame: Approximately 4 months
Time to maximum concentration (Tmax)
PK Parameter
Time frame: Approximately 4 months
Apparent terminal half-life (t1/2)
PK Parameter
Time frame: Approximately 4 months
Trough concentration (Ctrough)
PK Parameter
Time frame: Approximately 4 months
Incidence of antidrug antibodies (ADAs)
Time frame: Approximately 4 months
Proportion of participants with CD4+ T-cell lymphocyte count >200 cells/µL
Time frame: Approximately 1 year
Proportion of participants with CD4+ T-cell lymphocyte count >200 cells/µL, with a minimum increase of 50 cells/µL
Time frame: Approximately 1 year
Duration of CD4+ T-cell lymphocyte count increases >200 cells/µL
The time from start of the first occurrence of CD4+ T-cell count increases to the level \>200 cells/µL to the first occurrence of CD4+ T-cell count to the level \<200 cells/µL
Time frame: Approximately 1 year
Duration of CD4+ T-cell lymphocyte count increases >200 cells/µL with a minimum increase of 50 cells/µL
The time from start of the first occurrence of CD4+ T-cell count increases to the level \>200 cells/µL to the first occurrence of CD4+ T-cell count to the level \<200 cells/µL with a minimum increase of 50 cells/µL
Time frame: Approximately 1 year
Change from baseline in CD4+ T-cell lymphocyte counts
The change from baseline in CD4+ T-cell lymphocyte counts will be summarized based on observed values.
Time frame: Approximately 1 year
Change from baseline in CD4+ T cell percentage
The change from baseline in CD4+ T cell percentage will be summarized based on observed values.
Time frame: Approximately 1 year
Change from baseline in CD8+ T-cell lymphocyte counts
The change from baseline CD8+ T-cell lymphocyte counts will be summarized based on observed values.
Time frame: Approximately 1 year
Change from baseline in CD4:CD8 ratio
The change from baseline in CD4:CD8 ratio will be summarized.
Time frame: Approximately 1 year
Change from baseline in Treg and other T-cell subsets
Time frame: Approximately 6 months
Proportion of subjects with HIV viral load <50 copies/mL
The proportion of subjects with HIV viral load \<50 copies/mL will be summarized.
Time frame: Approximately 1 year
Proportion of subjects with fatal or non-fatal acquired immunodeficiency syndrome (AIDS) related opportunistic disease or death from any cause
Time frame: Approximately 1 year
Start is estimated for Dec 2022; primary completion for May 2024, 17 months later.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brentuximab Vedotin
Acquired Immunodeficiency Syndrome →